US › Healthcare

Actinium Pharmaceuticals Inc (ATNM)

US · Healthcare · Biotechnology

$1.13+6.60%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$35.0M

Net profit

$27.9M

EPS

$0.89

EPS estimate

$-0.20

Net margin

79.7%

EPS came in at 0.89 against a street estimate of -0.20 — a beat of 545.0%.

Key statistics

Market cap

$35.5M

P/E

3.2

Forward P/E

8.5

P/B

1.22

Book value

$0.96

EPS (TTM)

$0.35

52-week high

$1.74

52-week low

$0.73

50-day MA

$1.09

200-day MA

$1.12

Beta

0.27

Analyst view

Analysts rate Actinium Pharmaceuticals Inc a buy (4 buy, 1 hold, 0 sell out of 5) with an average price target of $3.60.

Shareholding

Insiders

8.08%

Institutions

17.30%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Actinium Pharmaceuticals Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.